FDA grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals, Ltd.

• Second RPD designation for QRX003; first was for Netherton Syndrome.
• If NDA approved, Quoin may receive a Priority Review Voucher (PRV), which can be sold or transferred.
• Phase 2 study expected to initiate in 2H 2026, enrolling up to 12 pediatric and adult PSS patients in U.S. and Europe.
• No approved treatments currently exist for Peeling Skin Syndrome.